BioTuesdays

HCW starts Antares Pharma at buy

Antares Pharmaceuticals

H.C. Wainwright initiated coverage of Antares Pharma (NASDAQ:ATRS) with a “buy” rating and $5 price target. The stock closed at $3.01 on June 22.

Analyst Corey Davis writes that Antares has been a long leader in complex injector device development and made the leap to a fully integrated, commercial stage, drug-device specialty pharmaceutical company in 2014, with the launch of Otrexup, which has been disappointing.

“The stock has now rebounded strongly off multi-year lows in the last year under new leadership, but we believe there is still more upside as its diversified business strategy (a combo of partnered and in-house assets) finally matures in the near future,” he added.

Antares is a sum-of-the-parts story, Mr. Davis said, and “we believe several of those parts could come into clarity within months.”

He cited a potential A/B-rated generic EpiPen approval (partnered with TEVA) in the third quarter this year; Antares’ own Xyosted testosterone PDUFA date in October this year; partnered generic Byetta approval/launch; and a partnered Makena auto injector, with an October 2017 PDUFA.

“We project cash flow breakeven in the second half of 2018 and overall profitability in 2019,” he added.

POWERED BY

Stay Ahead in Healthcare & Life Sciences